Nature

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve patient survival.
Forbes

A New Immunotherapy For Cancer: PD-L2

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
FiercePharma

FDA sets an example through Eli Lilly, Innovent's PD-1, rocking the boat for future contenders: analyst

The FDA's harsh stance against Eli Lilly and Innovent Biologics' PD-1 application could spell trouble for other cancer immunotherapy latecomers. (Sarah Silbiger / Stringer / Getty Images News) By ...
Nature

Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer

We investigated the role of tumor cell-intrinsic PD-L1 signaling in the epithelial−mesenchymal transition (EMT) in non-small-cell lung cancer (NSCLC) and the role of EMT as a predictive biomarker for ...